SEC 13F Intelligence

Commodore Capital LP / SYRE

Commodore Capital LP’s Spyre Therapeutics Inc Position

Does Commodore Capital LP own Spyre Therapeutics Inc (SYRE)? Yes — 1.91M shares worth $96M (+5.58% of its 13F portfolio) as of Q1 2026, down from 2.39M shares the prior filed quarter.

Position Value
$96M
Q1 2026
Shares
1.91M
% of Portfolio
+5.58%
Quarters Held
11
currently held

Position History SYRE

Reported value by quarter
Q3 ’23: $1MQ3 ’23Q4 ’23: $41MQ1 ’24: $71MQ1 ’24Q2 ’24: $47MQ3 ’24: $58MQ3 ’24Q4 ’24: $46MQ1 ’25: $32MQ1 ’25Q2 ’25: $30MQ3 ’25: $33MQ3 ’25Q4 ’25: $78MQ1 ’26: $96MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.91M$96M+5.58%
Q4 20252.39M$78M+5.21%
Q3 20251.99M$33M+1.63%
Q2 20251.99M$30M+2.10%
Q1 20251.99M$32M+2.36%
Q4 20241.99M$46M+3.39%
Q3 20241.99M$58M+3.65%
Q2 20241.99M$47M+3.19%
Q1 20241.88M$71M+4.78%
Q4 20231.88M$41M+3.54%
Q3 2023116.3K$1M+0.17%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Commodore Capital LP’s full portfolio or all institutional holders of SYRE.